Crinetics Pharmaceuticals (CRNX) Finished Goods (2025 - 2026)
Crinetics Pharmaceuticals' (CRNX) quarterly Finished Goods came in at $29000.0 in Q1 2026, up 61.11% quarter-over-quarter from $18000.0 in Q4 2025.
Crinetics Pharmaceuticals (CRNX) Finished Goods (2025 - 2026) Analysis & Trends
Crinetics Pharmaceuticals' Finished Goods history runs 2 years deep, the most recent figure standing at $29000.0 for Q1 2026.
- On a quarterly basis, Finished Goods changed N/A year-over-year to $29000.0 in Q1 2026; TTM through Mar 2026 was $29000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $18000.0, changed N/A from the prior year.
- Finished Goods improved to $29000.0 in Q1 2026 per CRNX's latest filing, from $18000.0 in the prior quarter.
- Across five years, Finished Goods topped out at $29000.0 in Q1 2026 and bottomed at $18000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - |
| 4 | BeOne Medicines | 472.68 Bn | 467.89 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.24 Bn | 114.99 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.33 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - |
| 8 | Argenx Se | 55.93 Bn | 50.75 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn |
| 10 | Crinetics Pharmaceuticals | 8.72 Bn | 7.43 Bn | 10.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29,000.00 |
| Dec 31, 2025 | 18,000.00 |